NRx Pharmaceuticals announced that the FDA Office of Generic Drugs has issued a preliminary bioequivalence determination for its preservative‑free ketamine ANDA, a key regulatory step toward approval in the summer of 2026.
The determination confirms that the agency has not identified any bioequivalence deficiencies, clearing a major hurdle that had delayed the company’s entry into the ketamine market. The FDA’s focus on domestic supply chain resilience and the absence of benzethonium chloride—a preservative with safety concerns—make the preservative‑free formulation a first‑in‑class product that could attract clinicians seeking safer options.
The generic ketamine market is estimated at $750 million annually. By securing the bioequivalence determination, NRx positions its KETAFREE™ product to capture a share of this market, while also reinforcing its dual‑track strategy that includes the NRX‑100 NDA for a novel depression indication and the HOPE Therapeutics clinical services platform that has begun generating revenue.
Financially, NRx reported an operating loss of $4 million in Q3 2025 and $240,000 in revenue from HOPE, with $7.1 million in cash and equivalents as of September 30 2025. The company’s cash runway is projected to sustain operations through July 2026, and it is preparing to release Q4 2025 earnings on March 13 2026, where analysts expect a loss of $0.09 per share and revenue of $7.525 million.
The FDA determination, combined with the company’s ongoing clinical and commercial initiatives, signals a significant reduction in regulatory risk and a clearer path to revenue generation, underscoring the strategic importance of the event for NRx’s long‑term growth prospects.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.